- Home
- QURE vs ELV Comparison
QURE vs ELV Comparison
Compare QURE & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- ELV
- Stock Information
- Founded
- QURE 1998
- ELV 1944
- Country
- QURE Netherlands
- ELV United States
- Employees
- QURE N/A
- ELV N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- ELV Medical Specialities
- Sector
- QURE Health Care
- ELV Health Care
- Exchange
- QURE Nasdaq
- ELV Nasdaq
- Market Cap
- QURE 725.4M
- ELV 91.2B
- IPO Year
- QURE 2007
- ELV N/A
- Fundamental
- Price
- QURE $14.47
- ELV $383.79
- Analyst Decision
- QURE Strong Buy
- ELV Buy
- Analyst Count
- QURE 10
- ELV 15
- Target Price
- QURE $37.20
- ELV $519.76
- AVG Volume (30 Days)
- QURE 2.1M
- ELV 1.8M
- Earning Date
- QURE 05-09-2025
- ELV 07-16-2025
- Dividend Yield
- QURE N/A
- ELV 1.78%
- EPS Growth
- QURE N/A
- ELV N/A
- EPS
- QURE N/A
- ELV 25.60
- Revenue
- QURE $20,201,000.00
- ELV $183,124,000,000.00
- Revenue This Year
- QURE $60.54
- ELV $11.16
- Revenue Next Year
- QURE $183.28
- ELV $7.13
- P/E Ratio
- QURE N/A
- ELV $14.99
- Revenue Growth
- QURE 6.30
- ELV 6.63
- 52 Week Low
- QURE $3.73
- ELV $357.45
- 52 Week High
- QURE $19.18
- ELV $567.26
- Technical
- Relative Strength Index (RSI)
- QURE 53.75
- ELV 42.71
- Support Level
- QURE $14.81
- ELV $368.75
- Resistance Level
- QURE $16.20
- ELV $384.59
- Average True Range (ATR)
- QURE 0.94
- ELV 14.67
- MACD
- QURE 0.03
- ELV -1.18
- Stochastic Oscillator
- QURE 53.62
- ELV 39.44
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About ELV Elevance Health Inc.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.